X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to jointly investigate a novel peripherally preferred melatonin receptor agonist, discovered by Ache, for a range of women’s health indications, starting with polycystic ovary syndrome (PCOS).
Lead Product(s): Undisclosed
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Recipient: Celmatix
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 08, 2023
Details:
Under the terms of the agreement, MSRD and Aché will collaborate to advance Aché’s novel compound ACH000029 through phase 1b clinical trials with the opportunity to expand the collaboration after those studies.
Lead Product(s): ACH000029
Therapeutic Area: Psychiatry/Psychology Product Name: ACH000029
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: McQuade Center for Strategic Research and Development
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 24, 2021
Details:
Nemera's multidose eye dropper Novelia® has been approved by ANVISA for the preservative-free formulations CLILON (Ketorolac 0,4% and 0,5%), a nonsteroidal anti-inflammatory drug that is used to treat moderately severe pain and inflammation, usually after surgery.
Lead Product(s): Ketorolac Trometamol
Therapeutic Area: Ophthalmology Product Name: Clilon
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Nemera
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
